Domača stranGLTO • NASDAQ
add
Galecto Inc
Prejšnji trg. dan.
5,09 $
Dnevni razpon
4,70 $ - 5,10 $
Letni razpon
4,40 $ - 23,50 $
Tržna kapitalizacija
6,28 mio. USD
Povprečni obseg
18,93 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | — | — |
Stroški poslovanja | 3,84 mio. | −34,42 % |
Čisti dohodek | −3,88 mio. | 52,27 % |
Čista dobičkovnost prihodkov | — | — |
Earnings per share | −3,39 | 32,03 % |
EBITDA | −3,83 mio. | 32,07 % |
Efektivna davčna stopnja | −0,18 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 19,68 mio. | −55,46 % |
Skupna sredstva | 23,38 mio. | −53,29 % |
Skupne obveznosti | 2,44 mio. | −80,73 % |
Celoten lastniški kapital | 20,94 mio. | — |
Shares outstanding | 1,32 mio. | — |
Razmerje P/B | 0,30 | — |
Donosnost sredstev | −37,89 % | — |
Donosnost kapitala | −43,02 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −3,88 mio. | 52,27 % |
Denar iz dejavnosti | −3,65 mio. | 56,81 % |
Denar iz naložb | 0,00 | −100,00 % |
Denar iz financiranja | — | — |
Neto sprememba denarnih sredstev | −3,18 mio. | −2.709,84 % |
Prost denarni tok | −2,08 mio. | 44,50 % |
Vizitka
Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark.
The company builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Galecto's lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, in which there is high unmet medical need. Wikipedia
Generalni direktor
Datum ustanovitve
2011
Sedež organizacije
Spletno mesto
Zaposleni
13
